BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16303035)

  • 21. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.
    Mainie I; Tutuian R; Castell DO
    J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
    Basu KK; Bale R; West KP; de Caestecker JS
    Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1187-92. PubMed ID: 12439112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors.
    Frazzoni M; Manno M; De Micheli E; Savarino V
    Dig Liver Dis; 2007 May; 39(5):415-21. PubMed ID: 17379591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients.
    Grigolon A; Cantù P; Savojardo D; Conte D; Penagini R
    J Clin Gastroenterol; 2008 Oct; 42(9):969-73. PubMed ID: 18719508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heartburn in primary care: problems below the surface.
    Holtmann G; Maldonado-Lopez E; Haag S
    J Gastroenterol; 2004 Nov; 39(11):1027-34. PubMed ID: 15580394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
    Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A;
    Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease.
    Schentag JJ; Goss TF
    Am J Hosp Pharm; 1993 Apr; 50(4 Suppl 1):S7-10. PubMed ID: 8097364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors.
    Pfefferkorn MD; Croffie JM; Gupta SK; Molleston JP; Eckert GJ; Corkins MR; Fitzgerald JF
    J Pediatr Gastroenterol Nutr; 2006 Feb; 42(2):160-5. PubMed ID: 16456408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolving issues in the management of reflux disease?
    Yuan Y; Hunt RH
    Curr Opin Gastroenterol; 2009 Jul; 25(4):342-51. PubMed ID: 19417644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
    Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
    Björnsson E; Abrahamsson H; Simrén M; Mattsson N; Jensen C; Agerforz P; Kilander A
    Aliment Pharmacol Ther; 2006 Sep; 24(6):945-54. PubMed ID: 16948806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders.
    Castell D
    Expert Opin Pharmacother; 2005 Nov; 6(14):2501-10. PubMed ID: 16259581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction. GERD warrants increased physician appreciation and improved treatment.
    Webb DD
    Postgrad Med; 2001 Oct; Spec No():5-10. PubMed ID: 11868429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacological management of gastroesophageal reflux disease.
    Lowe RC; Wolfe MM
    Minerva Gastroenterol Dietol; 2004 Sep; 50(3):227-37. PubMed ID: 15729198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The diagnosis of gastroesophageal reflux disease.
    Dughera L; Navino M; Cassolino P; Pellicano R
    Minerva Gastroenterol Dietol; 2007 Jun; 53(2):143-52. PubMed ID: 17557042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review article: alternative approaches to the long-term management of GERD.
    Fennerty MB
    Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():39-44. PubMed ID: 16303036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GERD and Barrett's esophagus: diagnostic and management strategies in the geriatric population.
    Morganstern B; Anandasabapathy S
    Geriatrics; 2009 Jul; 64(7):9-12. PubMed ID: 19586085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the acidity index and integrated intragastric acidity in 645 patients presenting with gastroesophageal reflux disease symptoms.
    Blonski WC; Shih GL; Brensinger CM; Katzka DA; Metz DC
    Scand J Gastroenterol; 2006 Apr; 41(4):382-9. PubMed ID: 16635904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.
    Miyamoto M; Haruma K; Kuwabara M; Nagano M; Okamoto T; Tanaka M
    J Gastroenterol Hepatol; 2007 May; 22(5):639-44. PubMed ID: 17444849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.